APC and amyotrophic lateral sclerosis: Of note, a previous study in the SOD1G93A ALS mouse model demonstrated that treatment of mice with an activated protein C (APC) mutant (5A-APC) protected blood-spinal cord barrier integrity and delayed onset of motor symptoms (Winkler et al., 2014), indicating there are multiple effective methods for targeting vascular defects in ALS.